0 165

Cited 83 times in

Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy

DC FieldValueLanguage
dc.contributor.author김자경-
dc.contributor.author박민찬-
dc.contributor.author박용범-
dc.contributor.author이수곤-
dc.date.accessioned2015-04-24T17:25:12Z-
dc.date.available2015-04-24T17:25:12Z-
dc.date.issued2009-
dc.identifier.issn0315-162X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105365-
dc.description.abstractOBJECTIVE: To investigate whether anti-tumor necrosis factor-alpha (TNF-alpha) therapy can influence the reactivation of hepatitis B virus (HBV) infection in inactive HBsAg carriers. METHODS: The medical records of 103 patients [59 with ankylosing spondylitis (AS), 41 with rheumatoid arthritis (RA), 2 with juvenile RA, and 1 with psoriatic arthritis] who had been treated with anti-TNF-alpha therapy were reviewed retrospectively. Data on seropositivity of HBV, HBV load, and serum aminotransferases prior to and after initiation of anti-TNF-alpha therapy were obtained. RESULTS: Eight patients were inactive HBsAg carriers, and all of them had normal liver function and undetectable HBV load prior to anti-TNF-alpha therapy. Reactivation of hepatitis B occurred in 1 patient during the course of anti-TNF-alpha therapy. After the third infusion of infliximab 5 mg/kg at Week 6, a blood test showed that the patient had normal liver function. When the patient returned for the fourth infusion of infliximab at Week 14, a blood test showed markedly elevated aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels (457 and 1054 IU/l, respectively) and increased viral DNA by HBV polymerase chain reaction (PCR). The fourth infliximab infusion was canceled, and entecavir 0.5 mg/day was prescribed. Then AST/ALT levels began to decrease and returned to normal range after 3 months. Followup HBV PCR showed negative results. CONCLUSION: We found 1 HBV reactivation case among 8 inactive HBsAg carriers following anti-TNF-alpha therapy. This finding supports the prophylactic use of antiviral agents in HBV carriers, even if they have normal liver function or an undetectable viral load-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfJournal of Rheumatology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleReactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSOO-JIN CHUNG-
dc.contributor.googleauthorJA KYUNG KIM-
dc.contributor.googleauthorMIN-CHAN PARK-
dc.contributor.googleauthorYONG-BEOM PARK-
dc.contributor.googleauthorSOO-KON LEE-
dc.identifier.doi10.3899/jrheum.081324-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00852-
dc.contributor.localIdA01470-
dc.contributor.localIdA01579-
dc.contributor.localIdA02889-
dc.contributor.localIdA03638-
dc.relation.journalcodeJ01738-
dc.identifier.urlhttp://www.jrheum.org/content/36/11/2416.long-
dc.contributor.alternativeNameKim, Ja Kyung-
dc.contributor.alternativeNamePark, Min Chan-
dc.contributor.alternativeNamePark, Yong Beom-
dc.contributor.alternativeNameLee, Soo Kon-
dc.contributor.alternativeNameJeong, Su Jin-
dc.contributor.affiliatedAuthorKim, Ja Kyung-
dc.contributor.affiliatedAuthorPark, Min Chan-
dc.contributor.affiliatedAuthorPark, Yong Beom-
dc.contributor.affiliatedAuthorLee, Soo Kon-
dc.contributor.affiliatedAuthorJeong, Su Jin-
dc.citation.volume36-
dc.citation.number11-
dc.citation.startPage2416-
dc.citation.endPage2420-
dc.identifier.bibliographicCitationJournal of Rheumatology, Vol.36(11) : 2416-2420, 2009-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.